Background Previous studies found that cell-free DNA (cfDNA) generated from tumors was
shorter than that from healthy cells, and selecting short cfDNA could enrich for tumor cfDNA …

Cell-free DNA (cfDNA) is short, extracellular, fragmented double-stranded DNA found in
plasma. Plasma of patients with solid tumor has been found to show significantly increased …

Circulating tumor-derived cell-free DNA (ctDNA) enables non-invasive diagnosis,
monitoring, and treatment susceptibility testing in human cancers. However, accurate …

Background Circulating cell-free DNA (cfDNA) in the plasma of cancer patients contains cell-
free tumour DNA (ctDNA) derived from tumour cells and it has been widely recognized as a …

The often dismal clinical outcomes for most cancers are due to the fact that cancer patients
diagnosed at advanced stages would miss the opportunities for curative treatments or …

Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of
tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is …

The structure, fragmentation pattern, length and terminal sequence of cell-free DNA (cfDNA)
is under the influence of nucleases present in the blood. We hypothesized that differences in …

Tumor-specific, circulating cell-free DNA (cfDNA) in liquid biopsy test is a novel promising
biomarker in the advancement of cancer management, including early diagnosis, screening …

Cell-free DNA (cfDNA) analysis is a minimally invasive method that can be used to detect
genomic abnormalities by directly testing a blood sample. This method is particularly useful …

Precision oncology is predicated upon the ability to detect specific actionable genomic
alterations and to monitor their adaptive evolution during treatment to counter resistance …